CBRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CBRE Group Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows mixed signals, with bearish technical indicators, declining financial performance, and insider selling activity. While analysts have upgraded the stock and hedge funds are buying, the lack of recent positive news, weak technical momentum, and declining financial metrics suggest it is better to wait for clearer signs of recovery or improvement before investing.
The stock is showing bearish technical indicators. The MACD histogram is negative and contracting, RSI is neutral at 30.713, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The price is near the support level of 140.407, which could act as a short-term floor, but overall momentum is weak.
Hedge funds are significantly increasing their holdings (+113.38% last quarter). Analysts from UBS and Goldman Sachs have recently upgraded the stock to Buy, citing strong industry trends and CBRE's position to benefit from AI and data assets. The stock has a 60% chance of gaining 5.27% in the next week and 6.12% in the next month.
Insiders are selling heavily, with an 799.30% increase in selling activity over the last month. Financial performance in Q4 2025 showed declining net income (-14.58% YoY), EPS (-12.03% YoY), and gross margin (-10.77% YoY). Additionally, there is no recent positive news or congress trading activity to support a strong buy case.
In Q4 2025, revenue increased by 11.77% YoY to $11.63 billion, but net income dropped by 14.58% YoY to $416 million. EPS also declined by 12.03% YoY to 1.39, and gross margin fell by 10.77% YoY to 16.91%. While revenue growth is a positive, declining profitability metrics are concerning.
Analysts are generally positive on CBRE. UBS upgraded the stock to Buy with a price target of $185, citing a rare buying opportunity and strong industry trends. Goldman Sachs also maintained a Buy rating, lowering the price target to $198 from $212, and highlighted CBRE's resilience to AI disruption. However, Keefe Bruyette recently lowered its price target to $170 from $192 while maintaining an Outperform rating.
